share_log

赛诺菲确认将以116亿美元收购Bioverativ

Sanofi confirms it will buy Bioverativ for $11.6 billion

新浪美股 ·  Jan 22, 2018 15:06

French Healthcare GroupSanofiIt has agreed to buy its American counterpart Bioverativ for 11.6 billion US dollars. Sanofi said the deal will boost the company's profits and strengthen the company's business in the field of rare disease treatment.

Sanofi agreed to buy all of Bioverativ's outstanding shares in cash at $105 per share, at a 64% premium over the latter's closing price on January 19, 2018. (End)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment